Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.78 USD
-0.07 (-3.78%)
Updated Apr 19, 2024 03:59 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CYCC 1.78 -0.07(-3.78%)
Will CYCC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CYCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYCC
New Strong Buy Stocks for October 17th
Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why
CYCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release
Other News for CYCC
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023